TH5487 is a potent, active-site inhibitor of the 8-oxoguanine DNA glycosylase (OGG1) enzyme, designed to block the initial step of base excision repair. It inhibits OGG1-catalyzed excision of 8-oxoguanine and formamidopyrimidine lesions with IC₅₀ values of 0.8 µM and 3.1 µM, respectively. TH5487 treatment induces genomic accumulation of 8-oxoG lesions, impairs OGG1 chromatin binding, and prevents incision events that lead to double-strand breaks under oxidative stress. This inhibitor is widely used to study OGG1 dynamics, backup glycosylase recruitment, and the role of oxidative DNA damage repair in cellular models.

OGG1:342 nM

Cell Line:Murine airway epithelial cell line (MLE 12); Diploid human small-airway epithelial cell (hSAECs). Concentration:5 μM. Incubation Time:1 hour

Animal Model:Eightweek-old female and male BALB/c mice. Dosage:8 mg/kg, 15 mg/kg, 30 mg/kg. Administration:Prophylactic intraperitoneally injection; 8-30 mg/kg; 1-9 hours

DMSO: 62.5 mg/mL (115.49 mM), Sonication is recommended.

10% DMSO+40% PEG300+5% Tween 80+45% Saline: 2 mg/mL (3.7 mM), Sonication is recommended.

10% DMSO+90% Saline: 6.25 mg/mL (11.55 mM), Suspension.